Ignite Creation Date:
2024-05-06 @ 2:30 PM
Last Modification Date:
2024-10-26 @ 1:31 PM
Study NCT ID:
NCT04331626
Status:
UNKNOWN
Last Update Posted:
2020-04-02
First Post:
2020-03-31
Brief Title:
Low-dose Gemcitabine Combined With Nivolumab for Second-line and Above Line Treatment of NSCLC
Sponsor:
Organization:
Henan Cancer Hospital
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
50
Enrollment Type:
ESTIMATED
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE4 |
Observational Models:
Time Perspective List:
Who Masked List: